

Attorney Docket No.: DC-0232  
Inventors: Hillary D. White  
Serial No.: 10/677,673  
Filing Date: October 2, 2003  
Page 3

**Amendments to the Specification:**

Please replace the paragraph beginning on page 9, line 14, with the following rewritten paragraph:

The delivery vehicle for this study was a gel formulation. It was chosen for use as a goal of the study was to identify a transdermal delivery system for hormones that would result in effective levels of hormones in blood as a way to reduce side effects of androgen therapy. The gel use for this study was a 1% w/w testosterone gel, USP grade. The daily gel dose applied was 0.75 grams; an expected bioavailability of 10% would deliver 0.75 mg ~~0.075-grams~~ testosterone over 24 hr. The gel was formulated for women by Bentley Pharmaceuticals, Inc. (North Hampton, NH) using good manufacturing practice standards, and is colorless, comfortable on the skin, and non-staining.